The Effect of Thyroid-Stimulating Hormone on Tumor Size in Differentiated Thyroid Carcinoma

详细信息    查看全文

• 作者：I. A. Ozemir ; B. Gurbuz ; B. Bayraktar ; S. Aslan ; A. Başkent…
• 关键词：Differentiated thyroid cancer ; Thyroid ; stimulating hormone ; Tumor size ; Microcarcinoma
• 刊名：Indian Journal of Surgery
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：77
• 期：3-supp
• 页码：967-970
• 全文大小：155 KB
• 参考文献：1.Pathak KA, Leslie WD, Klonisch TC, Nason RW (2013) The changing face of thyroid cancer in a population-based cohort. Cancer Med 2(4):537–44CrossRef PubMed
  2.Canadian Cancer Society’s Steering Committee on Cancer Statistics (2012) Pp 7–60 in Canadian cancer statistics. 2012. Canadian Cancer Society, Toronto, ON
  3.Kim D, Park JW (2013) Clinical implications of preoperative thyrotropin serum concentrations in patients who underwent thyroidectomy for nonfunctioning nodule(s). J Korean Surg Soc 85(1):15–9CrossRef PubMed PubMedCentral
  4.Shi L, Li Y et al (2012) Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: result os 1,870 Chinese patients with thyroid nodules. Endocr J 59(11):973–80CrossRef PubMed
  5.Zafon C, Obiols G, Baena JA, Castellvi J, Dalama B, Mesa J (2012) Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. J Thyroid Res. doi:10.​1155/​2012/​530721
  6.Zhu C, Zheng T (2009) A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004. Thyroid 19:1061–6CrossRef PubMed PubMedCentral
  7.Cooper DS, Doherty GM (2009) American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer: revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214CrossRef PubMed
  8.Malcolm H, Wheeler MD (1998) Invited commentary prevalence of thyroid cancer in hyperthyroid patients treated by surgery. World J Surg 22:473–478CrossRef
  9.Goretzki PE, Koob R, Koller T, Simon R, Branscheid D, Clark OH, Röher HD (1986) The effect of thyrotropin and cAMP on DNA synthesis and cell growth of human thyrocytes in monolayer culture. Surgery 100(6):1053–61PubMed
  10.Zaballos MA, Santisteban P (2013) FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesis. Mol Endocrinol 27(1):50–62CrossRef PubMed
  11.Boelaert K (2009) The association between serum TSH concentration and thyroid cancer. Endocr-Relat Cancer 16(4):1065–72CrossRef PubMed
  12.Hancock BW, Bing RF, Dirmikis SM, Munro DS, Neal FE (1977) Thyroid carcinoma and concurrent hyperthyroidism. Cancer 39:298–302CrossRef PubMed
  13.Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA (2006) Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91(11):4295–4301CrossRef PubMed
  14.Franco AT, Malaguarnera R et al (2011) Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci 108:1615–20CrossRef PubMed PubMedCentral
  15.Haymart MR, Repplinger DJ et al (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93:809–14CrossRef PubMed PubMedCentral
  16.Gerschpacher M, Göbl C et al (2010) Thyrotropin serum concentrations in patients with papillary thyroid microcancers. Thyroid 20:389–92CrossRef PubMed
  17.Kamer E, Ünalp HR (2011) Incidental papillary microcarcinoma of thyroid. Endocrinolojide Diyalog 8(3):116–9
  18.Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 295(18):2164–7CrossRef
  19.Leenhardt L, Grosclaude P (2004) Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the french thyroid cancer committee. Thyroid 14(12):1056–60CrossRef PubMed
  20.Gülben K, Berberoğlu U (2008) Incidental papillary microcarcinoma of the thyroid factors affecting lymph node metastasis. Langenbeck's Arch Surg 393:25–29CrossRef
  21.Lloyd R, De Lellis R (2004) World Health Organization classification of tumors: pathology and genetics of tumors of the endocrine organs. IARC Press, Lyon
  22.Noguchi S, Yamashita H (2008) Papillary microcarcinoma. World J Surg 32(5):747–53CrossRef PubMed PubMedCentral
  23.Fiore E, Rago T et al (2009) Lower levels of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer 16:1251–60CrossRef PubMed
  24.Fiore E, Rago T et al (2010) l -Thyroxine treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27,914 patients. Endocr Relat Cancer 17:231–9CrossRef PubMed
  25.Jin J, Machekano R, McHenry CR (2010) The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease. Am J Surg 199(3):294–8CrossRef PubMed
  
• 作者单位：I. A. Ozemir (1) (3)
  B. Gurbuz (1)
  B. Bayraktar (1)
  S. Aslan (1)
  A. Başkent (2)
  H. Yalman (1)
  R. Yigitbasi (1)
  O. Alimoglu (1)
  
  1. Department of General Surgery, Medical Faculty, Göztepe Training and Research Hospital, İstanbul Medeniyet University, Istanbul, Turkey
  3. Küçüksu Mah., Asma Sok, Eston Kandilli Evleri Sitesi, A-12 Blok, Kandilli, Üsküdar, 34684, Istanbul, Turkey
  2. Department of General Surgery, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey
  
• 刊物主题：Surgery; Pediatric Surgery; Neurosurgery; Plastic Surgery; Cardiac Surgery; Thoracic Surgery;
• 出版者：Springer India
• ISSN：0973-9793

文摘

We evaluated the correlation between serum thyroid-stimulating hormone (TSH) levels and tumor size and other invasiveness parameters of tumor in patients with differentiated thyroid carcinoma (DTC). Several clinical studies have reported that TSH may also have a role as a regulator of the development and function of the thyroid gland. It is currently not clear whether TSH is involved in the existence of thyroid cancer or progression of thyroid cancer or both. Patients with DTC who underwent thyroid surgery between 2003 and 2008 were included this study. Preoperative serum T3, T4, and TSH levels were compared with the size and invasiveness of cancer, retrospectively. DTC was observed in 110 patients over the 5-year period. Seventy-seven (70 %) of them were euthyroid and classified as the “normal-TSH group” (NTG), and 33 (30 %) have an overt or subclinical hyperthyroidism, classified as the “low-TSH group” (LTG). The mean tumor diameter in the LTG was found to be 8.91 ± 8.03 mm; however, it was found to be 18.19 ± 16.24 mm in the NTG. There were significantly differences among the groups related to the diameter of tumor (p = 0.001). Microcarcinoma was determined in 36 patients (46.8 %) in the NTG and 23 patients (69.7 %) in the LTG (p = 0.027). Although there were no significant differences, tumor capsule invasion (33.8 vs. 18.2 %, p = 0.099) and lymphovascular invasion (16.9 vs. 6.1 %, p = 0.130) rates were higher in the NTG. These findings suggest that TSH has effects on growing and proliferation of not only normal thyroid cells but also cancer cells in DTC. This study revealed that serum TSH level can be explored as an important factor that affects the size and invasiveness of tumor in DTC.